All sponsors

Akeso $9926.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS67
PHASE 3 / 2-323
RECRUITING32
READOUTS ≤12 MONTHS26
READOUT SLIPPED >6 MO40%

Delay Index: of 40 active trials registered more than a year ago, 16 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Akeso on the live radar map → 📅 $9926.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Ivonescimab (SMT112 or AK112) Injection
NCT05184712
P3Active, not recruitingNon-Squamous Non-small Cell Lung Cancer3222023-03-10 (-10 mo)
AK104
NCT05319431
P2Active, not recruitingUnresectable, Non-metastatic Hepatocellular Carcinoma602023-08-15
AK112
NCT05499390
P3Active, not recruitingAdvanced Non-small-cell Lung Cancer3982024-01-29 (-5 mo)
Cadonilimab
NCT05960955
P2RecruitingResectable Gastric or Gastroesophageal Junction Adenocarcinoma902024-11-30
AK112, Carboplatin, Paxlitaxel
NCT05840016
P3Active, not recruitingAdvanced Squamous Non Small Cell Lung Cancer5322025-02-28 (+2 mo)
AK104
NCT05859750
P2RecruitingPancreatic Cancer782025-06
AK120
NCT06756126
P2Not yet recruitingAtopic Dermatitis242025-06-30
AK104
NCT05990127
P3Not yet recruitingLocally Advanced or Metastatic NSCLC6422025-08-05
AK112
NCT05247684
P2Active, not recruitingResectable Non-small Cell Lung Cancer902025-08-18 (+24 mo)
AK117
NCT04900350
P1/2Active, not recruitingMyelodysplastic Syndrome1362025-09 (+28 mo)
AK117
NCT04980885
P1/2Active, not recruitingAcute Myeloid Leukemia682025-09 (+26 mo)
AK104
NCT06371157
P3RecruitingHepatocellular Carcinoma4692025-10-25
AK109
NCT04982276
P1/2RecruitingGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma1382025-12-30 (+43 mo)
AK104
NCT04982237
P3Active, not recruitingCervical Cancer4452025-12-30 (+9 mo)
AK117
NCT06196203
P2RecruitingHigher-risk Myelodysplastic Syndromes902026-01
AK104
NCT05489289
P3RecruitingHepatocellular Carcinoma5702026-01-28 (+12 mo)
Penpulimab
NCT04974398
P3Active, not recruitingNasopharyngeal Carcinoma2962026-02-23 (+32 mo)
AK117
NCT06387420
P1/2Not yet recruitingACUTE MYELOID LEUKEMIA; AML1802026-04
AK104-305
NCT05235516
P3Active, not recruitingLocally Advanced Cervical Carcinoma6362026-05
AK127 in combination with AK112
NCT05951608
P1/2Active, not recruitingAdvanced Solid Tumors2162026-05-01 (+10 mo)
AK104
NCT06560112
P2RecruitingRecurrent Ovarian Cancer1722026-05-01
AK119
NCT05846867
P1/2Active, not recruitingColorectal Cancer1702026-05-08 (+24 mo)
AK112
NCT05382442
P2Active, not recruitingMetastatic Colorectal Cancer2542026-05-15 (+43 mo)
AK112
NCT06530251
P1/2RecruitingHepatocellular Carcinoma2802026-06
AK112
NCT05904379
P1/2Active, not recruitingAdvanced Non-small-cell Lung Cancer2332026-06-30 (+14 mo)
AK112
NCT04736823
P2Active, not recruitingNSCLC2652026-07 (+42 mo)
AK139
NCT07436234
P2Not yet recruitingSeasonal Allergic Rhinitis1112026-09-30
AK112, Gemcitabine, Cisplatin
NCT06591520
P3Active, not recruitingBiliary Tract Cancer6822026-10 (-9 mo)
Cadonilimab (AK104)
NCT06617416
P3RecruitingNSCLC (Non-small Cell Lung Cancer)5602026-10-28
cadonilimab
NCT06341335
P3RecruitingGastric and Gastroesophageal Junction Adenocarcinoma5062026-11
AK104+lenvatinib
NCT06984718
P2Not yet recruitingHCC; Hepatocellular Carcinoma1202026-11-30
AK112
NCT06767527
P3RecruitingTriple-Negative Breast Cancer (TNBC)4162026-12
AK129(dose 1)
NCT06943820
P1/2RecruitingNon-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC)2302026-12
AK119
NCT05689853
P1/2RecruitingSolid Tumor, Adult872026-12 (+30 mo)
AK139
NCT07436221
P2Not yet recruitingAsthma1602026-12-27
AK117
NCT05227664
P2Active, not recruitingMetastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer1202026-12-30 (+47 mo)
AK112, Cadonilimab, nab-paclitaxel, gemcitabine
NCT06646055
P1/2Active, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma1102026-12-30
AK112
NCT05229497
P1/2Active, not recruitingAdvanced Malignant Tumors1542026-12-31 (+47 mo)
AK117 in combination with AK112
NCT06601335
P3RecruitingHead and Neck Squamous Cell Carcinoma5102027-01
AK112
NCT06951503
P3RecruitingColorectal Adenocarcinoma5602027-01-13
VG2025
NCT07357220
P1/2Not yet recruitingColorectal Cancer With Hepatic Metastases722027-02-28
AK109+AK104
NCT05142423
P1/2RecruitingAdvanced Solid Tumor1982027-04 (+55 mo)
AK139
NCT07755371
P2Not yet recruitingChronic Rhinosinusitis With Nasal Polyps (CRSwNP)752027-04-30
AK112
NCT06938321
P1/2RecruitingBiliary Tract Cancer1352027-05
NSCLC
NCT06928389
P3RecruitingNon-Small Cell Lung Cancer5362027-05
TT-00420 (tinengotinib)
NCT07052253
P2RecruitingHepatocellular Carcinoma (HCC)1002027-05-10
Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine
NCT06953999
P3RecruitingPancreatic Cancer9992027-05-14
NCT06767540
NCT06767540
P3Not yet recruitingAtopic Dermatitis1982027-07-10
AK139
NCT07883213
P2Not yet recruitingPrurigo Nodularis (PN)1322027-08
AK112
NCT07114315
P2RecruitingPancreatic Cancer1602027-08
AK146D1 for injection
NCT07669779
P2RecruitingAdvanced Non Small Cell Lung Cancer (NSCLC)3482027-08-30
AK146D1 for injection
NCT07591090
P2RecruitingAdvanced Breast Cancer2002027-09-01
AK112 low dose
NCT06686030
P2RecruitingPlatinum-sensitive Ovarian Cancer1502027-10
AK139
NCT07502222
P2Not yet recruitingModerate-to-Severe Atopic Dermatitis1682027-11
AK129
NCT06642792
P1/2RecruitingClassic Hodgkin Lymphoma2802027-11
AK104(SC)
NCT07449780
P3Not yet recruitingGastric / Gastroesophageal Junction Adenocarcinoma4222027-11-17
Ivonescimab
NCT07245446
P2RecruitingExtensive-stage Small Cell Lung Cancer (ES-SCLC)1802027-12
AK138D1
NCT07560124
P1/2Not yet recruitingBreast Cancer2862028-06-06
AK138D1
NCT07623356
P1/2RecruitingNon-Small Cell Lung Cancer2652028-06-18
AK146D1 for injection
NCT07636772
P2Not yet recruitingUrothelial Carcinoma (UC)1322028-08-24
AGA TKI NSCLC
NCT07158840
P2Not yet recruitingNon-Small Cell Lung Cancer602028-09
AK112-311
NCT07010263
P3RecruitingSmall Cell Lung Cancer5602028-12-31
AK139
NCT07875426
P2Not yet recruitingChronic Spontaneous Urticaria2012029-01-08
Cadonilimab
NCT07023315
P3RecruitingGastric and Gastroesophageal Junction (GEJ) Adenocarcinoma7602029-07
G/GEJ
NCT07700979
P3RecruitingGastric / Gastroesophageal Junction Adenocarcinoma9002029-08-18
Cadonilimab (AK104)
NCT07263919
P2RecruitingResectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma902030-03
Cadonilimab (AK104)
NCT07412613
P3RecruitingResectable Colon Cancer; MSI-H/dMMR Colorectal Cancer3862030-06-15